Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Urology · Renal Angiomyolipoma

What Happens Next If a Fat-Poor Kidney AML Looks Cancerous?

At a Glance

When a fat-poor angiomyolipoma looks like kidney cancer, the next step is usually dedicated CT or MRI reviewed by a kidney-mass specialist, with biopsy considered if uncertainty remains; monitoring or treatment depends on the tumor and your health.

In this answer

3 sections

01

Upgrading the Imaging

02

Specialist Review and Biopsy

03

Management Options: Surveillance to Surgery

When a kidney scan reveals a mass suspected to be a fat-poor angiomyolipoma (a tumor that lacks obvious fat), distinguishing it from kidney cancer is a common diagnostic challenge. Because both can look nearly identical on initial imaging, the goal is not to immediately rush to surgery, nor is it to delay care, but to quickly gather more detailed information [1][2]. Clarifying the diagnosis helps your care team choose the safest appropriate treatment and preserves as much functioning kidney tissue as possible [3][4]. This typically involves upgrading to dedicated kidney scans, reviewing the images with specialists, and potentially performing a needle biopsy [5].

Upgrading the Imaging

If your initial scan could not confirm the diagnosis, your doctors will likely recommend specialized imaging protocols.

The Role of CT and MRI Scans

Dedicated computed tomography (CT) or magnetic resonance imaging (MRI) scans capture images in multiple phases to look at the tumor’s physical properties. While no single feature can reliably rule cancer in or out, radiologists look for clues that may favor a fat-poor AML:

  • Unenhanced attenuation (CT): How dense the tumor looks before contrast dye is given. Fat-poor AMLs may appear dense [2][3].
  • Enhancement patterns (CT/MRI): How the tumor absorbs contrast dye. A rapid, homogeneous (even) uptake of dye may favor fat-poor AML, whereas some cancers absorb dye unevenly [2][6].
  • T2-weighted imaging (MRI): Fat-poor AMLs often appear dark (low T2 signal) [7][3].
  • Chemical-shift imaging (MRI): A technique to detect microscopic fat. However, finding microscopic fat does not confirm a benign AML, as clear-cell kidney cancer can also contain it [8][9].

Because other conditions—such as papillary renal cell carcinoma—share many of these features, these scans must be carefully interpreted by an expert radiologist [7][3].

Why Ultrasound is Not Enough

While an ultrasound is excellent for identifying classic AMLs that contain large amounts of fat, it cannot reliably tell the difference between a fat-poor AML and kidney cancer [10][11]. The echo patterns overlap too much, meaning a diagnosis should never be based solely on an ultrasound [12].

Comparing Prior Scans

If you have had older abdominal scans, doctors will compare them to assess the tumor’s growth. While a rapidly growing mass is concerning, stability or slow growth does not prove a tumor is benign [10][13]. Both benign AMLs and some kidney cancers can grow slowly, so growth is just one piece of the puzzle.

Specialist Review and Biopsy

When imaging leaves room for doubt, your case requires a structured, individualized approach.

Expert Review and Factors Affecting Your Plan

Complex cases benefit from review by a multidisciplinary tumor board (a collaborative meeting of urologists, radiologists, oncologists, and pathologists) [14][15]. If a formal board is not available, seek review by specialists experienced with complex renal masses. They will personalize your plan based on:

  • Tumor details: Size, location, and the presence of blood vessel aneurysms inside the mass.
  • Your health: Kidney function, symptoms, use of blood-thinning medications, and pregnancy plans.
  • Underlying conditions: Any history of genetic conditions like Tuberous Sclerosis Complex.

Percutaneous Kidney Biopsy

If cancer cannot be ruled out, the team may recommend a percutaneous renal mass biopsy (inserting a needle through the back to take a tiny sample) [5].

  • Benefits: A biopsy can accurately diagnose the tumor type and help direct treatment or avoid unnecessary surgery for a benign AML [16][17].
  • Limitations: A biopsy can suffer from sampling error—meaning the needle might miss a malignant part of the tumor [16][18]. A benign or “non-diagnostic” result (where the sample doesn’t contain enough tissue to make a diagnosis, occurring in up to 14% of cases) does not automatically mean you are cancer-free [16][19]. In such cases, repeat biopsy, surveillance, or treatment may be discussed.
  • Risks: While generally safe, risks include pain, infection, and bleeding (which requires careful management of blood-thinning medications) [16][20].

Management Options: Surveillance to Surgery

Depending on the final assessment, your care team will discuss several management options [4].

Active Surveillance

If the mass is small, asymptomatic, and highly likely to be benign, you may be a candidate for active surveillance [13][21]. This does not mean “doing nothing.” It involves scheduled imaging and clinical check-ups. Predefined changes—such as meaningful growth or new symptoms—would prompt a reconsideration of treatment [22].

Important Safety Warning: If you are on surveillance for a suspected AML, seek urgent medical assessment for sudden severe flank or abdominal pain, fainting, marked weakness, or visible blood in the urine, as these can be signs of internal bleeding.

When Treatment is Needed

Intervention may be recommended if a biopsy shows cancer, if the results remain uncertain, or if a benign AML poses a high risk of bleeding [5][23]. Historically, AMLs over 4 centimeters were automatically treated, but modern guidelines treat this as a flexible threshold; decisions are individualized based on symptoms, aneurysms, and growth rate rather than size alone [24].

Additionally, if pathology suspects epithelioid angiomyolipoma—a rare variant with malignant potential—prompt specialist review and individualized oncologic management are required, which often includes surgical excision [25][15].

When treatment is necessary, options include:

  • Selective Arterial Embolization: Blocking the blood vessels that feed the tumor to shrink it and prevent bleeding [4][26].
  • Thermal Ablation: Using heat or cold to destroy small tumors without surgery [27].
  • Partial Nephrectomy: Surgically removing only the tumor while preserving the rest of the kidney [4][27].
  • Radical Nephrectomy: Removing the entire kidney, typically reserved for very large or deeply invasive tumors [28][29].

Common questions in this guide

What is usually done first when a fat-poor angiomyolipoma may be kidney cancer?
Doctors usually obtain dedicated, multiphase CT or MRI scans and ask an experienced radiologist to review them. If the images still cannot distinguish a benign angiomyolipoma from cancer, a needle biopsy may be considered. The plan also depends on the mass’s size and location, your kidney function and symptoms, and bleeding risks.
Can CT or MRI prove that a fat-poor angiomyolipoma is not cancer?
No. CT and MRI can provide useful clues, but fat-poor angiomyolipomas and some kidney cancers can look alike, so no single imaging feature reliably rules cancer in or out. Review by a radiologist experienced with kidney masses is important.
Does a benign or non-diagnostic biopsy completely rule out kidney cancer?
No. A needle sample can miss a cancerous area, and a non-diagnostic sample may not contain enough tissue to identify the tumor. Your team may discuss a repeat biopsy, monitoring, or treatment based on the imaging and your overall clinical picture.
When can a fat-poor angiomyolipoma be monitored instead of treated?
Active surveillance may be considered when the mass is small, causes no symptoms, and appears highly likely to be benign. It involves scheduled imaging and clinical visits rather than no follow-up. Meaningful growth or new symptoms can lead to a change in the plan.
What treatments are available if the kidney mass needs treatment?
Options include selective arterial embolization, thermal ablation, and partial nephrectomy, which removes the mass while preserving kidney tissue. Radical nephrectomy, or removal of the entire kidney, is generally reserved for very large or deeply invasive tumors. The best choice depends on the tumor’s features, kidney function, and overall health.
What symptoms could mean that an angiomyolipoma is bleeding?
Sudden severe flank or abdominal pain, fainting, marked weakness, or visible blood in the urine may signal internal bleeding. Seek urgent medical assessment if any of these symptoms occur, especially while the mass is being monitored.
Does a 4-centimeter angiomyolipoma always need treatment?
No. The 4-centimeter threshold is not an automatic treatment rule. Doctors also consider symptoms, blood-vessel aneurysms, growth rate, bleeding risk, imaging findings, and overall kidney health.

Related questions

How Long Should a Stable Renal Angiomyolipoma Be Monitored? What Growth Rate Is Fast for a Renal Angiomyolipoma? Can a Renal Angiomyolipoma Turn Into Kidney Cancer? Can I Exercise Safely with a Renal Angiomyolipoma? When Is Genetic Testing Recommended for TSC and Kidney AMLs?
Show more
Can Blood Thinners Raise Renal Angiomyolipoma Bleeding Risk? Is 4 cm Still the Treatment Cutoff for Renal Angiomyolipoma? Is MRI Better Than CT for Renal AML Surveillance Imaging? Small Sporadic Renal AML: How Often Should It Be Scanned? Can a Renal AML Cause Flank Pain Without Hematuria? Why Does an Angiomyolipoma Aneurysm Increase Bleeding Risk? Can a Small Renal Angiomyolipoma Rupture or Bleed? Do Multiple Bilateral AMLs Mean Tuberous Sclerosis? How Accurate Is a Biopsy for Fat-Poor AML vs Kidney Cancer? Is Ultrasound Reliable for Monitoring a Renal Angiomyolipoma? What Does Epithelioid Renal AML Mean? Can It Spread? What Happens During a Renal Mass Biopsy for Fat-Poor AML? What Do Classic, Fat-Poor, and Epithelioid Renal AMLs Mean? What Tests Are Needed for TSC After Finding a Kidney AML?

Get notified when new evidence is published on angiomyolipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (29)
  1. 1

    Lipid-poor renal angiomyolipoma: Differentiation from clear cell renal cell carcinoma using wash-in and washout characteristics on contrast-enhanced computed tomography.

    Xie P, Yang Z, Yuan Z

    Oncology letters 2016; (11(3)):2327-2331 doi:10.3892/ol.2016.4214.

    PMID: 26998171
  2. 2

    Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation.

    Tanaka H, Fujii Y, Tanaka H, et al.

    International journal of urology : official journal of the Japanese Urological Association 2017; (24(7)):511-517 doi:10.1111/iju.13354.

    PMID: 28600877
  3. 3

    Computed Tomography and Magnetic Resonance Findings of Fat-Poor Angiomyolipomas.

    Potretzke AM, Potretzke TA, Bauman TM, et al.

    Journal of endourology 2017; (31(2)):119-128 doi:10.1089/end.2016.0219.

    PMID: 27897036
  4. 4

    Update on the Diagnosis and Management of Renal Angiomyolipoma.

    Flum AS, Hamoui N, Said MA, et al.

    The Journal of urology 2016; (195(4 Pt 1)):834-46.

    PMID: 26612197
  5. 5

    Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.

    Park BK

    AJR. American journal of roentgenology 2017; (209(4)):826-835 doi:10.2214/AJR.17.17973.

    PMID: 28726505
  6. 6

    Angiomyolipoma with minimal fat: differentiation of morphological and enhancement features from renal cell carcinoma at CT imaging.

    Sung CK, Kim SH, Woo S, et al.

    Acta radiologica (Stockholm, Sweden : 1987) 2016; (57(9)):1114-22 doi:10.1177/0284185115618547.

    PMID: 26663389
  7. 7

    Characterization of small (<4cm) solid renal masses by computed tomography and magnetic resonance imaging: Current evidence and further development.

    Schieda N, Lim RS, McInnes MDF, et al.

    Diagnostic and interventional imaging 2018; (99(7-8)):443-455 doi:10.1016/j.diii.2018.03.004.

    PMID: 29606371
  8. 8

    Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma.

    Jhaveri KS, Elmi A, Hosseini-Nik H, et al.

    AJR. American journal of roentgenology 2015; (205(1)):W79-86 doi:10.2214/AJR.14.13245.

    PMID: 26102422
  9. 9

    Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis.

    Chen LS, Zhu ZQ, Wang ZT, et al.

    European radiology 2018; (28(5)):1854-1861 doi:10.1007/s00330-017-5141-0.

    PMID: 29178029
  10. 10

    Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex.

    Buj Pradilla MJ, Martí Ballesté T, Torra R, Villacampa Aubá F

    Clinical kidney journal 2017; (10(6)):728-737 doi:10.1093/ckj/sfx094.

    PMID: 29225800
  11. 11

    Renal angiomyolipoma: preoperative identification of atypical fat-poor AML.

    Farrell C, Noyes SL, Tourojman M, Lane BR

    Current urology reports 2015; (16(3)):12 doi:10.1007/s11934-015-0484-z.

    PMID: 25677233
  12. 12

    Sonographic Features of Small (< 4 cm) Renal Tumors With Low Signal Intensity on T2-Weighted MR Images: Differentiating Minimal-Fat Angiomyolipoma From Renal Cell Carcinoma.

    Park KJ, Kim MH, Kim JK, Cho KS

    AJR. American journal of roentgenology 2018; (211(3)):605-613 doi:10.2214/AJR.17.18909.

    PMID: 30040467
  13. 13

    Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy.

    Bhatt JR, Richard PO, Kim NS, et al.

    European urology 2016; (70(1)):85-90 doi:10.1016/j.eururo.2016.01.048.

    PMID: 26873836
  14. 14

    Radiologist's Disease: Imaging for Renal Cancer.

    Chung A, Raman SS

    The Urologic clinics of North America 2023; (50(2)):161-180 doi:10.1016/j.ucl.2023.01.006.

    PMID: 36948664
  15. 15

    Renal Epithelioid Angiomyolipomas: Clinicopathological Features, Diagnosis, and Management.

    Rallis KS

    Cancer diagnosis & prognosis 2025; (5(6)):788-795 doi:10.21873/cdp.10495.

    PMID: 41179323
  16. 16

    Systematic Review and Meta-analysis on Renal Tumor Biopsy: Accuracy, Safety, and Impact on Clinical Decision-making.

    Mjaess G, Nicolazzini M, Amparore D, et al.

    European urology 2026; doi:10.1016/j.eururo.2026.07.002.

    PMID: 42498608
  17. 17

    Update on Indications for Percutaneous Renal Mass Biopsy in the Era of Advanced CT and MRI.

    Lim CS, Schieda N, Silverman SG

    AJR. American journal of roentgenology 2019; (212(6)):1187-1196 doi:10.2214/AJR.19.21093.

    PMID: 30917018
  18. 18

    Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses.

    Abel EJ, Heckman JE, Hinshaw L, et al.

    The Journal of urology 2015; (194(4)):886-91.

    PMID: 25837535
  19. 19

    Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature.

    Patel HD, Johnson MH, Pierorazio PM, et al.

    The Journal of urology 2016; (195(5)):1340-1347 doi:10.1016/j.juro.2015.11.029.

    PMID: 26901507
  20. 20

    Long-Term Follow-Up in Patients Undergoing Renal Mass Biopsy: Seeding is not Anecdotal.

    Staehler M, Rodler S, Brinkmann I, et al.

    Clinical genitourinary cancer 2024; (22(2)):189-192 doi:10.1016/j.clgc.2023.10.012.

    PMID: 37985332
  21. 21

    Evolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study.

    Keles A, Iplikci A, Arikan O, et al.

    The aging male : the official journal of the International Society for the Study of the Aging Male 2024; (27(1)):2346308 doi:10.1080/13685538.2024.2346308.

    PMID: 38709235
  22. 22

    New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.

    Restrepo JCÁ, Millan DAC, Sabogal CAR, et al.

    Journal of kidney cancer and VHL 2022; (9(1)):33-41 doi:10.15586/jkcvhl.v9i1.177.

    PMID: 35096516
  23. 23

    Renal Angiomyolipoma in a Young Woman With Tuberous Sclerosis: A Case Report.

    Lema DD, Ngowi BN, Lekei E, et al.

    Clinical case reports 2026; (14(1)):e71866 doi:10.1002/ccr3.71866.

    PMID: 41550395
  24. 24

    Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.

    Hatano T, Egawa S

    Asian journal of surgery 2020; (43(10)):967-972 doi:10.1016/j.asjsur.2019.12.008.

    PMID: 31959574
  25. 25

    Renal epithelioid angiomyolipoma: A case report.

    Li H, Zhang X, Zhao Q, et al.

    Oncology letters 2023; (26(3)):409 doi:10.3892/ol.2023.13995.

    PMID: 37600337
  26. 26

    The Role of Interventional Radiology Techniques in the Management of Renal Angiomyolipomas.

    Kiefer RM, Stavropoulos SW

    Current urology reports 2017; (18(5)):36 doi:10.1007/s11934-017-0687-6.

    PMID: 28299630
  27. 27

    Imaging and Nonsurgical Management of Renal Masses.

    Jorgenson LC, Navin PJ, Adamo D, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240093 doi:10.1148/rg.240093.

    PMID: 39700039
  28. 28

    Giant renal hilar angiomyolipoma with Mayo level II venous tumor thrombus: a rare case report and literature review.

    Pan W, Li Y, Fan C, et al.

    BMC urology 2026; (26(1)).

    PMID: 41826918
  29. 29

    Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex.

    Mach M, Maciejewski K, Ostrowski T, et al.

    Cureus 2024; (16(8)):e66200 doi:10.7759/cureus.66200.

    PMID: 39105203

This page is for informational purposes only and does not constitute medical advice. A urologist and other kidney-mass specialists should interpret your scans and biopsy results and recommend care for your specific situation.